Agriculture Generates 7.54 Research Records for Every Unit of Corporate Activity While Genomics Carries the Lowest Vehicle Rate at 2.6% as a 22-Fold Translation Gap Spans 15 Themes

InnoDexis has published its latest Cross-Stream Intelligence Report — The Translation Gap — mapping 4,440 validated Research-stream records against 10,126 validated Corporate-stream records on the common window from 1 July to 21 August 2026, aligned across a fifteen-theme taxonomy. The report reveals that the translation ratio — research share divided by corporate share — varies twenty-two-fold across themes, spanning Agriculture and Food at 7.54x to Cybersecurity at 0.24x. Only 4.1% of research records name any formal commercialisation vehicle — a patent application, spin-off, startup formation, or licensing deal — and the correlation between the translation gap and the formal vehicle rate across fifteen themes is −0.61, confirming that the gap tracks commercialisation machinery rather than science quality.

Key Findings

The fifteen-theme translation ratio spans a range too wide to be noise. Agriculture and Food leads at 7.54x, followed by Quantum at 4.72x, Genomics and Cell Therapy at 4.11x, Climate and Sustainability at 3.73x, Space and Satellite at 3.17x, and Biotech and Drug Discovery at 3.13x — all themes where science is running materially ahead of visible commercialisation. At the other end, Cybersecurity at 0.24x and AI Compute Infrastructure at 0.28x describe commerce-led environments where the market is moving on activity the published literature is barely capturing. Two readings are available for a low ratio and they are not the same thing: Cybersecurity's 0.24x almost certainly reflects closed research happening inside vendors and never reaching publication, while AI compute infrastructure's 0.28x reflects settled science and activity that by nature produces commercial announcements rather than papers.

The translation gap tracks the commercialisation machinery on the research side, not the quality of the science. Plotting each theme's translation ratio against the share of its research records naming a formal vehicle produces a correlation of −0.61 across fifteen themes. Where universities are filing patents, spinning out companies, and signing licences, the corporate stream shows corresponding activity. Where they are publishing and stopping, it does not. The two themes sitting well above the trend line — Quantum at 4.72x with a 7.7% vehicle rate and Advanced Materials at 2.62x with 11.4% — combine abundant science with functioning institutional commercialisation machinery, identifying them as the themes where step-change corporate activity is most likely to arrive next.

The research-to-commerce funnel makes the attrition visible in absolute terms. Of 4,440 validated research records, 98.4% name a downstream application and 45.4% discuss industry transfer, but only 4.1% — 180 records — name any formal commercialisation vehicle. Venture investment appears on 0.5% of records — 22 in total. Government grants appear on 39.2% of records, corporate funding on 9.1%, and venture investment on 0.5%, meaning public funding is 4.3 times the corporate funding rate and 79 times the venture rate. The handoff from state finance to private capital is happening at a rate the report identifies as the pipeline's rate-limiting step rather than a background condition.

The four-quadrant taxonomy produces structurally distinct strategic responses. Quantum is the clearest loaded spring: 209 research records against 101 corporate ones, yet corporate records score 6.42 with 45% rated High investment attractiveness — high quality, low volume — with 15 quantum research records already naming a patent, spin-off, or licence. Genomics and Cell Therapy is the most striking stranded-science case: a 4.11x ratio and the lowest vehicle rate of all 15 themes at 2.6%, despite corporate records scoring 6.45 with 43% High investment attractiveness — commercial appetite plainly exists while the translation apparatus is absent from the published record. Converting themes — Robotics, Energy Storage, and AI Compute Infrastructure — carry the highest vehicle rates and are identified as useful for calibration rather than discovery.

The geographic inversion is the largest single asymmetry in the dataset. Germany accounts for 38.0% of research-stream country mentions and 2.5% of corporate ones. The United States runs the other way: 28.3% of research and 43.8% of corporate. The report is explicit that much of the German share is a source artefact driven by a dense German-language institutional press channel with no corporate-stream equivalent, but the underlying pattern survives a like-for-like test: German research records name a formal vehicle on 3.7% against the US 5.3%, and carry corporate funding on 5.5% against the US 15.8%, while government grant rates are similar at 36.0% and 42.8%. The difference is not in how the science is funded — it is in whether industry is standing next to it.

Of the 400 most active research institutions, 121 appear somewhere in the corporate record for the same window through entity co-occurrence matching. The NIH leads corporate mentions at 44, followed by Siemens at 43 — the clearest hybrid institution, with 12 research records and 43 corporate mentions appearing on both sides of the pipeline within the same seven weeks. MIT carries 94 research records against 16 corporate mentions; Yale 74 against 10; Stanford 3 against 31. A publisher-heavy institution with a rising research count and a flat corporate count is identified as the profile that precedes a licensing or spin-out event — a signal only the combined streams can produce.

Strategic Insight and Trend Analysis

The most consequential structural finding of the Translation Gap report is the confirmation that publication volume is the wrong leading indicator for commercial follow-through. Themes with large research bases and weak vehicle rates — Agriculture, Genomics, Climate — are not failing to commercialise because the science is weaker; they are failing because the institutional machinery that moves science out of universities is less present in their disclosed records. The −0.61 correlation between translation ratio and vehicle rate is strong enough to be a working predictor across fifteen themes with no within-theme quality variation required as an explanation.

This finding reframes the analytical priority for cross-stream intelligence. The vehicle rate — not the publication count, not the citation volume, not the significance field — is what the corporate stream is responding to. A research record naming a spin-off, patent, startup, or licence is the signal the market follows; everything upstream of it is necessary but not sufficient. The four fields that constitute a formal vehicle are populated on 1.5%, 1.9%, 1.4%, and 0.4% of research records respectively — sparse enough that a dedicated extraction improvement on these four fields alone would materially improve the predictive value of the entire research stream.

The loaded-spring quadrant is where the early-warning proposition is clearest. Quantum and Advanced Materials each combine a high translation ratio, a vehicle rate above the median, and high-quality but low-volume corporate activity. The constraint in both is neither discovery nor institutional will — the science is abundant and the legal structures are being built. The theme whose translation ratio falls first between now and the next quarterly cycle will be the one closest to converting, and monitoring that directional change requires both streams on a common window. Neither stream produces it alone.

Global and Industry Implications

For corporates and R&D teams, the quadrant taxonomy provides a directly actionable technology-scouting strategy. Loaded-spring themes — Quantum, Advanced Materials, Semiconductors and Photonics, and Power Generation and Grid — warrant early-warning coverage prioritised ahead of market momentum, because the commercialisation machinery is already running and the constraint is timing rather than institutional will. Stranded-science themes — particularly Genomics, Space, and Biotech — identify the specific domains where corporate licensing and partnership engagement would encounter high-quality science with minimal competition for deal flow, since the published record shows commercial appetite from the corporate side without a corresponding institutional vehicle on the research side.

For investors and capital allocators, the 121 bridged institutions provide a directly usable sourcing map for the current window. Publisher-heavy institutions with high research counts and flat corporate mentions — MIT at 94 research records against 16 corporate mentions, Yale at 74 against 10 — are identified as the profiles that precede licensing and spin-out events, and monitoring the directional change in their corporate mention count over successive cycles is the earliest available signal of an imminent translation event. The 0.5% venture investment rate across 4,440 research records confirms that the private capital handoff is structurally thin, and that the 22 records carrying venture investment represent the most specific early-stage investment cohort the Research stream produces in this window — a cohort small enough to review individually and concentrated enough to be actionable.

For policymakers and national innovation bodies, the funding architecture documented in the funnel is the most direct policy-relevant finding in the report. Government grants appear at 4.3 times the corporate funding rate and 79 times the venture rate across 4,440 Research-stream records. Policy instruments that increase the vehicle rate — not publication volume, not grant volume — are what the correlation of −0.61 identifies as the lever most directly connected to corporate follow-through. The German-US comparison is the most specific evidence for this: German and US research records carry similar government grant rates at 36.0% and 42.8% respectively, but German records carry corporate funding at 5.5% against the US 15.8% and formal vehicles at 3.7% against 5.3%, confirming that the gap between the two national ecosystems lies in whether industry is standing next to the science rather than in the level of public investment.

InnoDexis Statement

"The translation gap is not random and it is not a function of science quality — it tracks whether universities are building the legal and corporate structures to move their research out, and the correlation with formal vehicle rate across fifteen themes is strong enough to treat that as a working leading indicator rather than a hypothesis," noted InnoDexis in its latest intelligence report.

Conclusion

The Cross-Stream Translation Gap report establishes that the ratio between research and corporate activity varies twenty-two-fold across themes, that this variation is explained by commercialisation machinery with a correlation of −0.61 rather than by science quality, and that only 4.1% of research records name the formal vehicle that the corporate stream is demonstrably responding to. Across 4,440 Research and 10,126 Corporate records on a common seven-week window, the evidence confirms Quantum and Advanced Materials as the highest-priority loaded-spring themes, Genomics as the sharpest stranded-science case, 121 bridged institutions providing a working InnoGraph linkage today, and the German-US funding comparison as the most precise available evidence that industry co-location rather than grant volume is the variable that separates converting from stranded science. As the translation index is computed monthly on a rolling common window, the vehicle-rate fields are improved through dedicated extraction, geographic rebalancing addresses the German channel concentration, and publisher-heavy institution profiles are monitored for corporate mention inflection, the Translation Gap framework will provide the most structurally differentiated cross-stream intelligence the InnoDexis platform has yet produced. The complete Cross-Stream Translation Gap July to August 2026 Report is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a global Innovation Intelligence platform that tracks, analyzes, and interprets breakthrough innovations, prototypes, and emerging technologies across industries and countries. Its intelligence helps corporates, investors, and policymakers understand the true structure and direction of global innovation. Learn more at innodexis.ai.